Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 17:8:335.
doi: 10.3389/fncel.2014.00335. eCollection 2014.

Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue

José A G Agúndez  1 , Félix J Jiménez-Jiménez  2 , Hortensia Alonso-Navarro  2 , Elena García-Martín  3
Affiliations

Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue

José A G Agúndez et al. Front Cell Neurosci. .

Abstract

Drug biotransformation is a crucial mechanism for facilitating the elimination of chemicals from the organism and for decreasing their pharmacological activity. Published evidence suggests that brain drug metabolism may play a role in the development of adverse drug reactions and in the clinical response to drugs and xenobiotics. The blood-brain barrier (BBB) has been regarded mainly as a physical barrier for drugs and xenobiotics, and little attention has been paid to the BBB as a drug-metabolizing barrier. The presence of drug-metabolizing enzymes in the BBB is likely to have functional implications because local metabolism may inactivate drugs or may modify the drug's ability to cross the BBB, thus modifying drug response and the risk of developing adverse drug reactions. In this perspective paper, we discuss the expression of relevant xenobiotic metabolizing enzymes in the brain and in the BBB, and we cover current advances and future directions on the potential role of these BBB drug-metabolizing enzymes as modifiers of drug response.

Keywords: CNS drug; blood–brain barrier; drug metabolizing enzymes; drug response; expression profiling.

PubMed Disclaimer

References

    1. Agúndez J. A., García-Martin E. (2014). “Importance of CYP2D6 genotype/activity testing and applications,” in CYP2D6: Genetics, Pharmacology and Clinical Relevance ed. Baumann P. (London: Future Medicine Ltd.) 118–133
    1. Agundez J. A., Garcia-Martin E., Alonso-Navarro H., Jimenez-Jimenez F. J. (2013). Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin. Drug Metab. Toxicol. 9 859–874 - PubMed
    1. Agundez J. A., Garcia-Martin E., Martinez C. (2009). Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5 607–620 - PubMed
    1. Aiba I., Yamasaki T., Shinki T., Izumi S., Yamamoto K., Yamada S., et al. (2006). Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids 71 849–856 - PubMed
    1. Bournique B., Lemarie A. (2002). Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 30 1149–1152 - PubMed

LinkOut - more resources